• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Daiichi Sankyo builds $152M ADC plant in China

    FIERCE PHARMA

    Quantum-Wild Ph 3 VANFLYTA® Trial Initiated for Newly Diagnosed AML

    BUSINESSWIRE

    AstraZeneca, Daiichi share data behind Dato-DXd do-over

    FIERCE BIOTECH

    Datopotamab Shows Clinical Activity in EGFR-Mutated Lung Cancer

    BUSINESSWIRE

    Daiichi Sankyo Highlights Oncology Progress at ESMO, SABCS & ASH

    BUSINESSWIRE

    Daiichi Sankyo Joins LabCentral Community as Platinum Sponsor

    PR NEWSWIRE

    NICE says AZ, Daiichi failed to propose fair price on Enhertu

    FIERCE PHARMA

    Daiichi Sankyo to Showcase TURALIO® at CTOS for Giant Cell Tumor

    BUSINESSWIRE

    Daiichi Sankyo partners Alteogen on subcutaneous Enhertu News

    PHARMAPHORUM

    Enhertu Wins 2024 Prix Galien USA Best Biotech Product

    BUSINESSWIRE

    Datopotamab Deruxtecan-Based Trials Start in Advanced NSCLC

    BUSINESSWIRE

    AZ, Daiichi promote better care for Black breast cancer patients

    FIERCE PHARMA

    MILOS Study Highlights Bempedoic Acid`s Potential In Dyslipidemia

    EXPRESSPHARMA

    ENHERTU® Gets Priority Review For HER2-Low Breast Cancer

    BUSINESSWIRE

    ENHERTU Granted Priority Review For HER2 Low Breast Cancer

    BUSINESSWIRE

    MILOS German Cohort Results Show Increase In LDL-C Goal With

    BUSINESSWIRE

    Datopotamab Deruxtecan Results In TROPION-Breast01 Trial

    BUSINESSWIRE

    Datopotamab Deruxtecan Final OS Results In Breast Cancer Trial

    BUSINESSWIRE

    AstraZeneca`s drug disappoints in breast cancer survival trial

    REUTERS

    Daiichi, AZ Launch Enhertu DTC Campaign

    FIERCE PHARMA

    Biopharma Leaders Discuss AI Implementation In Marketing

    FIERCE PHARMA

    Merck, Daiichi`s ADC Lung Cancer Trial Shows Promise Despite Deaths

    BUSINESSWIRE

    DS-9606 Shows Promise In Patients With Advanced Solid Tumors

    BUSINESSWIRE

    AZ, Daiichi build case for Enhertu in breast cancer patients with brain metastases

    FEIRCE PHARMA

    ENHERTU Shows Activity In HER2+ Breast Cancer With Brain Metastases

    BUSINESSWIRE

    Novel TROP2 Biomarker Predicts Outcomes In NSCLC TROPION-Lung01 Trial

    BUSINESSWIRE

    Ifinatamab Deruxtecan Shows Promise In Small Cell Lung Cancer Trial

    BUSINESSWIRE

    Daiichi Sankyo Unveils New ADC Research in Multiple Cancers at WCLC and ESMO

    BUSINESSWIRE

    Daiichi study finds gender inequality in European cardiovascular care

    FIERCE PHARMA

    Daiichi Sankyo Light on Inequalities and Unmet Needs With Cardio Disease

    BUSINESSWIRE

    ENHERTU Gets US Breakthrough Status For HER2 Low/Ultralow Breast Cancer

    BUSINESSWIRE

    EMA Validates ENHERTU For HER2 Low/Ultralow Metastatic Breast Cancer

    BUSINESSWIRE

    Merck Advances Lung Cancer Strategy With Daiichi Deal And Combo Plans

    FIERCE BIOTECH

    First Patient Dosed In IDeate-Lung02 Trial Of Ifinatamab Deruxtecan

    PHARMABIZ

    IDeate-Lung02 Phase 3 Trial Of Ifinatamab Deruxtecan Initiated

    BUSINESSWIRE

    Enhertu stalls as AstraZeneca, Daiichi navigate `harder yards` for ADC star

    FIERCE PHARMA

    Daiichi Sankyo Opens New Affiliate for Oncology in Greece

    BUSINESSWIRE

    Without Pfizer appeal, Daiichi closes long-running ADC patent with $47M win

    FIERCE PHARMA

    Arbitration Dispute Between Daiichi Sankyo and Seagen Ends

    BUSINESSWIRE

    US FDA declines to approve Merck-Daiichi`s `guided missile` cancer drug

    REUTERS

    FDA rejects Merck`s first ADC in Daiichi partnership

    FIERCE PHARMA

    Patritumab Deruxtecan BLA Submission Receives Complete Response Letter From FDA

    BUSINESSWIRE

    Daiichi Sankyo’s Ezharmia Receives Japanese Approval For T-Cell Lymphoma

    PHARMABIZ

    Mika Collaborates with AstraZeneca and Daiichi for Breast Cancer Treatment

    GLOBENEWSWIRE

    Bempedoic Acid Cut CVD Risk Across Patient Groups Per CLEAR Outcomes

    BUSINESSWIRE

    RevolKa enters master service agreement with Daiichi Sankyo

    PHARMABIZ

    RevolKa Signs Master Service Agreement with Daiichi Sankyo

    CONTRACT PHARMA

    AstraZeneca-Daiichi`s Dato-DXd didn`t prove OS benefit in ph. 3

    FIERCE BIOTECH

    Tropion-Lung01: Nsclc Vs Chemo Clinically Meaningful Improvement

    BUSINESSWIRE

    Holistic Cv Care Recommendations: From European Multidisciplinary Think Tank

    BUSINESSWIRE

    RevolKa Signed Master Service Agreement with Daiichi Sankyo

    BUSINESSWIRE

    Japanese pharma firm Daiichi Sankyo sets up new research sites in US, Germany

    BIOSPECTRUM ASIA

    NILEMDO, NUSTENDI Approved In EU For Cholesterol Lowering

    BUSINESSWIRE

    Daiichi Sankyo Highlights Cancer Care Progress At ASCO

    BUSINESSWIRE

    AZ, Daiichi tout Enhertu win in earlier, broader HER2-low cancer

    FIERCE PHARMA

    US FDA approves Daiichi, AstraZeneca drug for treatment of solid tumors

    REUTERS

    Daiichi Sankyo`s Enhertu (fam-trastuzumab deruxtecan-nxki) Receives Suppl Approval in the U.S.

    FDA

    ENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy

    BUSINESSWIRE

    Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients

    BUSINESSWIRE

    AZ & Daiichi Sankyo’s BLA for Dato-DXd accepted in the US for breast cancer

    INDIANPHARMAPOST

    Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.